Discover cutting-edge studies on carcinogenesis, biomarkers, and targeted therapeutic approaches
Discover how SMAPs (Small Molecule Activators of PP2A) can disarm KRAS by awakening the dormant tumor suppressor PP2A in KRAS-driven cancers.